Int J Med Sci 2004; 1(2):116-125. doi:10.7150/ijms.1.116
A Randomized Study of Epithelial Ovarian Cancer: Is Chemotherapy Useful after Complete Remission?
GOCCNE Group (Gruppo Oncologico Cooperativo Clinico Nord-Est ovaio), Padua, Italy
Nicoletto MO, Tumolo S, Falci C, Donach M, Visonà E, Rosabian A, Nascimben O, Cima GP, Vinante O, Azzoni P, Fiorentino MV. A Randomized Study of Epithelial Ovarian Cancer: Is Chemotherapy Useful after Complete Remission?. Int J Med Sci 2004; 1(2):116-125. doi:10.7150/ijms.1.116. Available from http://www.medsci.org/v01p0116.htm
Objective. The aim of this study is to verify whether consolidation chemotherapy with Cisplatin improves disease-free survival and/or overall survival in patients affected by epithelial ovarian cancer.
Methods. A multicenter study examined 122 randomized patients in complete remission as judged by laparoscopy or laparotomy following first-line chemotherapy consisting of ACy (Adriamycin + Cyclophosphamide), PCy (Cisplatin + Cyclophosphamide), or Mitoxantrone + Carboplatin. Sixty-one of these patients were treated with 3 cycles of 5-Fluorouracil (FU) 500 mg/m2 for 5 days followed by Cisplatin at 100 mg/m2 on the 6th or 7th day every 28 days; the other 61 received no further treatment (nihil group).
Results. Sixty patients in the Cisplatin arm were evaluable. There were 36 relapses in the FU+Cisplatin arm and 30 in the nihil arm. Peritoneal relapses were 25% for Cisplatin treatment vs. 16.4 % for nihil. There were 29 deaths in the Cisplatin arm vs. 27 for nihil. Median overall survival time (95 months with Cisplatin vs. 96 months in the nihil group) and median disease-free survival (66 months with Cisplatin vs. 73 in the nihil group) were similar in both arms (p=0.66 and p=0.41, respectively). There were no significant differences in tumor stage and grade between the two arms. Seven patients presented a second neoplasm during follow-up: six in the nihil arm, but only one patient in the Cisplatin arm. Death in these patients was due to the second neoplasm and not to progression of ovarian cancer.
Conclusion. Three courses of additional platinum+FU treatment after five cycles of first-line chemotherapy without FU produced no increase in overall survival or disease-free survival.
Keywords: Epithelial Ovarian Cancer, Consolidation Chemotherapy, Cisplatin, Fluorouracil, Absence of Residuum